Trial Profile
Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms APOMORPHEE
- 06 May 2022 Status changed from active, no longer recruiting to completed as per results published in the Lancet Neurology
- 01 May 2022 Primary endpoint (Change from baseline PDSS2 score (Parkinsons Disease Sleep Scale) at the end of the sequence) has been met as per results published in the Lancet Neurology
- 01 May 2022 Results published in the Lancet Neurology